[12] Patent
[11] Patent No.:GC0009346  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/141399
Date of the Decision to Grant the Patent:11/Dec/2018

[21] Application No.:GC 2014-28231

[22] Filing Date:2/11/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
PCT
11/10/2014
PCT/CN2014/088409

[72] Inventors:1- Jeffrey T. BAGDANOFF،2- Yu Ding،3- Wooseok HAN،4- Zilin HUANG،5- Patrick LEE،6- Mika LINDVALL،7- Sabina PECCHI،8- Keith Bruce PFISTER،9- Daniel POON،10- Vivek RAUNIYAR،11- Xiaojing Michael WANG،12- Qiong ZHANG،13- Shejin ZHU،14- Jianguang Zhou،15- Qun Jiang،16- Zhongcheng Min،17- Xiang Kou،18- Jeff Xianming Jin،19- Yue Pan

[73] Owner: Novartis AG, Lichtstrasse 35 4056, Basel , Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/4418; A61P 35/00; C07D 213/73, 241/20, 401/04, 401/06, 401/12, 403/06, 405/04, 405/14, 409/04, 413/14 (2006.01)

[56] Cited Documents:

-WO 2004016597 A2 (VERTEX PHARMA [US]; COCHRAN JOHN [US]; GREEN JEREMY [US]; HALE MICHAEL) 26 February 2004  
Examiner: PH. Sarah A. AlGrainies

[54] AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS
[57] Abstract: The present invention provides a compound of Formula (I) or a salt thereof; (I)and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
No. of claims: 21     No. of figures: 4


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.